Data Mining Status of FDA's Efforts

Paul J. Seligman, M.D., M.P.H.

Director

CDER/Office of Pharmacoepidemiology
and Statistical Science (OPaSS)



Background

- Cooperative Research and Development Agreement (CRADA)
 - -FDA and Lincoln Technologies
 - -Purpose: to develop data mining software (WebVDME)
 - -March 2003 July 2005
- Decision made to put WebVDME into production



The Year In Review....

- Many tasks needed to prepare for production
 - System Development Lifecycle (IT) obligations
 - User Acceptance Testing
 - User training
 - -Contract negotiation, award



Production Use

- WebVDME 5.1 now available for use by all safety evaluators, epidemiologists in CDER's Division of Drug Risk Evaluation (DDRE)
- Strengthens and complements existing pharmacovigilance tools
 - Exact details of use still being worked out



Future Directions

- Expanded application
 - medication error surveillance
 - assessment of safety in clinical trials
 - signal detection in electronic longitudinal medical records, claims data
- Research
 - enhanced methods (e.g., assessing the role of polypharmacy in adverse events)

